AMA resolution calls for ad moratorium

Share this article:
The American Medical Association will advocate a mandatory moratorium on consumer advertising for new drugs.

At an AMA house of delegates meeting in Chicago last month, the group's membership passed a resolution recommending that the FDA adopt a moratorium on ads for new drugs. However, the organization did not specify a time-frame for the ad ban, instead suggesting that the FDA use its discretion based on the available scientific evidence for a drug's safety and efficacy.

“A temporary moratorium on DTC advertising of prescribed drugs and medical devices will benefit both the patient and the physician,” said AMA president-elect Ronald Davis, M.D.

The AMA's recommendation largely parallels existing PhRMA guidelines on DTC, which call for companies to “spend an appropriate amount of time to educate health professionals about a new medicine or a new therapeutic indication before commencing the first DTC advertising campaign,” but leave the interim up to the manufacturer, asserting that flexibility is necessary to allow for the urgency with which a new drug may be needed.

“AMA's vision of a DTC moratorium looks like government censorship, not patient empowerment, free speech or enlightened public policy,” said John Kamp, executive director of the Coalition for Healthcare Communications. “PhRMA's DTC Principles put the decision to advertise where it belongs, in the hands of the companies that know the most about their drugs and the information needs of doctors and patients.”

The AMA also called for all drug ads to be pre-approved by the FDA and for equal space to be allotted to risks and benefits in advertising.

Share this article:

Next Article in News

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union